Our Story
Protego Bio was founded on the conviction that protein misfolding diseases represent one of the most significant unmet medical needs of our time.
Our co-founders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, led the pioneering work behind tafamidis—the first disease-modifying therapy for transthyretin amyloidosis and a landmark validation of pharmacological chaperones. Years later, they reunited with a shared vision: to extend this proven approach to a broader set of protein misfolding diseases.
Building on decades of foundational research and drug development experience, Protego Bio is advancing a new generation of small molecule therapies designed to stabilize proteins, address the root cause of disease, and deliver meaningful outcomes for patients.
We are not starting from scratch—we are building from one of the most important successes in the field, with the ambition to do it again.
